An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Clinical trial NCT01618136 · COMPLETED

Trial details

NCT number: NCT01618136
Sponsor: Eisai Limited
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Malignant Solid Tumour Ovarian Cancer Triple Negative Breast Cancer Advanced Melanoma B-cell Malignancy, Low-grade

Start date: 2012-01-01
Primary completion: 2015-07-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.